VAXCYTE INC. - COMMON STOCK

Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

02 2 2024 17:39:14 提供 Nasdaq GlobeNewswire

Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

01 2 2024 15:05:49 提供 Nasdaq GlobeNewswire

Vaxcyte Announces Pricing of $750 Million Public Offering

30 1 2024 22:37:41 提供 Nasdaq GlobeNewswire

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

30 1 2024 15:01:28 提供 Nasdaq GlobeNewswire

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

29 1 2024 07:30:33 提供 Nasdaq GlobeNewswire

Vaxcyte Appoints Whitney Jones as Chief People Officer

16 1 2024 15:01:00 提供 Nasdaq GlobeNewswire

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

04 1 2024 15:01:42 提供 Nasdaq GlobeNewswire

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

04 12 2023 17:35:00 提供 Nasdaq GlobeNewswire

Vaxcyte Appoints Jacks Lee to Board of Directors

28 11 2023 07:30:00 提供 Nasdaq GlobeNewswire

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

27 11 2023 15:00:00 提供 Nasdaq GlobeNewswire

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

09 11 2023 07:30:00 提供 Nasdaq GlobeNewswire

Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

06 11 2023 15:03:00 提供 Nasdaq GlobeNewswire

Vaxcyte to Present at Upcoming Investor Conferences

31 10 2023 15:05:00 提供 Nasdaq GlobeNewswire

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

19 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)

16 10 2023 07:00:00 提供 Nasdaq GlobeNewswire

Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

19 9 2023 15:05:00 提供 Nasdaq GlobeNewswire

Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update

08 8 2023 15:03:00 提供 Nasdaq GlobeNewswire

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

11 7 2023 07:30:00 提供 Nasdaq GlobeNewswire

Vaxcyte to Present at the Jefferies Healthcare Conference

01 6 2023 15:05:00 提供 Nasdaq GlobeNewswire

Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

08 5 2023 15:03:00 提供 Nasdaq GlobeNewswire